About Callidus Biopharma
Callidus Biopharma is a Healthcare company based in Doylestown (United States) founded in 2010, and was acquired by Amicus Therapeutics in November 2013. Enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Callidus Biopharma has raised $4.61 million across 1 funding round from investors including Amicus Therapeutics. The company was acqui-hired. Its focus areas include Life Sciences, Metabolic Diseases and Drugs. Its legal entity is Callidus Biopharma, Inc. Its competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Callidus Biopharma is a drug discovery company focused on best-in-class enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Callidus novel technology platform is based on attaching a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body. The companys therapeutics offer the potential to significantly reduce the amount of drug that needs to be infused, which translates to patient and medical benefits of better efficacy, shorter infusion times, reduced immunogenicity, and greater convenience. Our lead program is for Pompe Disease but we are also applying our IGF2 technology to other LSDs to improve drug targeting and efficacy. We have also created a more stable enzyme which has the potential to be a superior ERT for Gaucher Disease.
- Headquarters Doylestown, United States
- Stage Acquired
- SectorsHealthcare
- Website callidusbiopharma.com
- Acquired by Amicus Therapeutics (Nov 2013)
- Legal Name Callidus Biopharma, Inc.
- Total Equity Funding$4.61M (USD)
in 1 rounds
- Latest Funding Round$4.61M (USD), Series A
Apr 2013
- Investors
- Acquired byAmicus Therapeutics
(Nov 2013)
Funding Insights of Callidus Biopharma
Callidus Biopharma has successfully raised a total of $4.61M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.61 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.61M
- Total Rounds 1
- Last Round Series A — $4.61M
- First Round $4.61M
(Apr 2013)
All 1 funding rounds of Callidus Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2013 | $4.61M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Callidus Biopharma
Callidus Biopharma has secured backing from 1 investor. Prominent investors backing the company include Amicus Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of therapies for rare and orphan diseases | 2002 | amicusrx.com | Philadelphia, United States |
Investor details for Callidus Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Callidus Biopharma
3 dated milestones of Callidus Biopharma across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Callidus Biopharma is founded.
- Funding First funding round of $4.6M.
- Exit Acquired by Amicus Therapeutics.
Competitors of Callidus Biopharma
Callidus Biopharma has 3 listed competitors in our database, 3 of them funded. They include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. |
Detailed competitors of Callidus Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Callidus Biopharma (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Callidus Biopharma
Complete news archive for Callidus Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Callidus Biopharma
Callidus Biopharma was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Callidus Biopharma is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Callidus Biopharma is a funded company, having raised a total of $4.61M across 1 funding round to date. The company's 1st funding round was a Series A of $4.61M, raised on Apr 2013.
Callidus Biopharma is a drug discovery company focused on best-in-class enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Callidus novel technology platform is based on attaching a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body. The companys therapeutics offer the potential to significantly reduce the amount of drug that needs to be infused, which translates to patient and medical benefits of better efficacy, shorter infusion times, reduced immunogenicity, and greater convenience. Our lead program is for Pompe Disease but we are also applying our IGF2 technology to other LSDs to improve drug targeting and efficacy. We have also created a more stable enzyme which has the potential to be a superior ERT for Gaucher Disease.
Callidus Biopharma's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
Callidus Biopharma has 1 investor. Key investors include Amicus Therapeutics.
Callidus Biopharma operates through Callidus Biopharma, Inc..
Yes. Callidus Biopharma was acquired by Amicus Therapeutics in November 2013.